Literature DB >> 19076368

Neurokinin-1 receptor expression and function in human macrophages and brain: perspective on the role in HIV neuropathogenesis.

Steven D Douglas1, Jian-Ping Lai, Florin Tuluc, Lynnae Schwartz, Laurie E Kilpatrick.   

Abstract

Substance P (SP) is upregulated in HIV infection in adult men and women, as determined by increased plasma levels. There is a reciprocal and bidirectional relationship between substance P and HIV in HIV-infected monocyte-derived macrophages and cell lines (e.g., THP-1). Substance P up-regulates HIV and HIV up-regulates SP protein expression. Neurokinin-1 receptor (NK1R) antagonists inhibit HIV infectivity through downregulation of the chemokine receptor, CCR5, and downregulation of HIV LTR. Neurokinin-1 receptor is expressed in full-length and truncated forms. The full-length NK1R is capable of signaling, whereas the truncated NK1R primes the chemokine receptor CCR5. Both full-length and truncated NK1R are expressed in several brain regions in human autopsy brains. SP-NK1R interactions have regulatory roles in inflammation and infection. The differential expression of truncated and full-length NK1R has important biological consequences. These include receptor-receptor interaction (e.g., NK1R-CCR5); changes in expression during cell differentiation (e.g., THP-1 cells); and differences in regional tissue distribution (e.g., differences in different brain regions). NK1R-SP receptor pathways are important cell regulatory pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19076368     DOI: 10.1196/annals.1418.007

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

Review 1.  Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.

Authors:  Steven D Douglas; Susan E Leeman
Journal:  Ann N Y Acad Sci       Date:  2010-11-22       Impact factor: 5.691

2.  Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS.

Authors:  Heather Vinet-Oliphant; Xavier Alvarez; Elizabeth Buza; Juan T Borda; Mahesh Mohan; Pyone P Aye; Florin Tuluc; Steven D Douglas; Andrew A Lackner
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

3.  Tachykinins and Neurokinin Receptors in Bone Marrow Functions: Neural-Hematopoietic Link.

Authors:  Tilman E Klassert; Shyam A Patel; Pranela Rameshwar
Journal:  J Receptor Ligand Channel Res       Date:  2010-04-01

4.  Retinal laser burn-induced neuropathy leads to substance P-dependent loss of ocular immune privilege.

Authors:  Kenyatta Lucas; Dimitris Karamichos; Rose Mathew; James D Zieske; Joan Stein-Streilein
Journal:  J Immunol       Date:  2012-06-27       Impact factor: 5.422

5.  Expression of substance P, neurokinin-1 receptor and immune markers in the brains of individuals with HIV-associated neuropathology.

Authors:  Sergei Spitsin; Kathleen E Stevens; Steven D Douglas
Journal:  J Neurol Sci       Date:  2013-08-02       Impact factor: 3.181

6.  Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.

Authors:  Sergei Spitsin; Florin Tuluc; John Meshki; Jian Ping Lai; Richard Tustin Iii; Steven D Douglas
Journal:  Neuroimmunomodulation       Date:  2013-07-05       Impact factor: 2.492

7.  Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.

Authors:  Sergei Spitsin; Pablo Tebas; Jeffrey S Barrett; Vasiliki Pappa; Deborah Kim; Deanne Taylor; Dwight L Evans; Steven D Douglas
Journal:  JCI Insight       Date:  2017-10-05

Review 8.  HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches.

Authors:  Marcus Kaul
Journal:  Curr Opin Neurol       Date:  2009-06       Impact factor: 5.710

9.  Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.

Authors:  Jeffrey S Barrett; Sergei Spitsin; Ganesh Moorthy; Kyle Barrett; Kate Baker; Andrew Lackner; Florin Tulic; Angela Winters; Dwight L Evans; Steven D Douglas
Journal:  J Transl Med       Date:  2016-05-26       Impact factor: 5.531

10.  Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Authors:  Pablo Tebas; Sergei Spitsin; Jeffrey S Barrett; Florin Tuluc; Okan Elci; James J Korelitz; Wayne Wagner; Angela Winters; Deborah Kim; Renae Catalano; Dwight L Evans; Steven D Douglas
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.